|Professor Mark Frydenberg|
The quality of prostate cancer care is improving according to new Monash University research published yesterday in The Medical Journal of Australia.
The five-year collaborative study between Monash University and 33 health institutions across Victoria, capturing 75 per cent of men diagnosed with prostate cancer in Victoria, found that processes of care were markedly improved, suggesting that the feedback from quality indicators was clinically valuable.
“We know that quality indicators are valuable tools to enable benchmarking performance of hospitals and clinicians. Where there is confidence in the quality of the data, providing these indicators back to health services and doctors has been shown to drive quality improvement.
“It’s terrific to see through quality indicators that the outcomes for men with prostate cancer are good and becoming even better,” said Professor Sue Evans, Head of the Clinical Registry Unit at Monash’s School of Public Health and Preventive Medicine, which houses the Movember-funded Australian Prostate Cancer Clinical Registry.
Prostate cancer continues to be the most commonly diagnosed cancer among Australian males. More than 18,000 Australian men are diagnosed with prostate cancer each year.
For men living with prostate cancer, there are a variety of treatment options now available which vary according to the stage of disease at diagnosis, but can include: active surveillance; hormone therapy; surgery; radiotherapy; or a combination of therapies.
“The Prostate Cancer Research International Active Surveillance (PRIAS) protocol guideline suggests men with low risk disease should be under active surveillance rather than receive immediate invasive treatment. Our Victorian research found the proportion of men with low risk disease who underwent active treatment declined over the five year period,” said Associate Professor Evans.
“As a practicing urologist it is satisfying to see such a high percentage of urologists committed measuring outcomes and improving quality of care,” said Professor Mark Frydenberg from the Department of Surgery at Monash University and Monash Health.
Professor Frydenberg said it can highlight areas of improvement such as clinical T stage documentation in histories, ensuring men with low risk cancer are ideally managed with surveillance, and ensuring that specialists can track potency and continence outcomes and measure for improvement with time.
“It is also gratifying to see a reduction in the pT2 margin rates suggesting better patient selection and better surgery to cure the disease.”
The mean percentage of PRIAS non-compliance had increased non-significantly from 45 per cent in 2009 to 55 per cent in 2010 and 50 per cent in 2011, but a downward trend was evident in 2012 (40 per cent) and 2013 (34 per cent); this achieved statistical significance in 2013 (P = 0.024).
The study also found that men diagnosed with high risk or locally advanced prostate cancer received treatment at a quicker rate across the duration of the study.
“This has the real potential to substantially improve quality of care, and also identify gaps in care such as in regional or rural areas that could be explored and inequities addressed,” said Professor Frydenberg.